Alpha Cognition Inc. Common Stock ACOG
8.73 USD -0.17 (-1.91%)
At closeNov 10, 2026, 4:00 PM EST
8.73 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
8.50 Day range 8.99
4.50 52-week range 10.14
- YTD
- +34.31%
- 1 year
- +39.46%
- Market cap
- 190.12M
- EPS (ttm)
- -1.32
- YTD return
- +34.31%
- 1-year return
- +39.46%
- Volume
- 107.83K
- Avg volume
- 126.30K
- Open
- 8.74
- Previous close
- 8.90
- Day's range
- 8.50 – 8.99
- 52-week range
- 4.50 – 10.14
5D +0.25 (+2.89%)
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 5.66
- 200-day average
- 5.66
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ACOG Revenue — quarterly 6.09M
ACOG Net income — quarterly -8.79M
ACOG EPS — quarterly -0.40
News
Alpha Cognition Announces Data From Its 180-Day Analysis Of Its CONVERGE PRogram For Patients Receiving ZUNVEYL, Donepezil, Galantamine Or Rivastigmine 
This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday 
B. Riley Securities Initiates Coverage On Alpha Cognition with Buy Rating, Announces Price Target of $21 
HC Wainwright & Co. Maintains Buy on Alpha Cognition, Raises Price Target to $20 
Alpha Cognition Q2 2026 Earnings Call Transcript 
Alpha Cognition Q2 EPS $(0.40) Misses $(0.39) Estimate, Sales $6.092M Beat $4.384M Estimate 
This Travelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday 
Raymond James Initiates Coverage On Alpha Cognition with Outperform Rating, Announces Price Target of $20 
Alpha Cognition Appoints Robert Wills As Board Chairman, Succeeding Len Mertz 
Alpha Cognition Enrolls First Patient In RESOLVE, Phase 4 Post-Marketing Clinical Study To Further Evaluate Tolerability Profile, Treatment Experience Associated With ZUNVEYL In Routine Clinical Practice
Your note
Sign in to keep a note on ACOG — it syncs with the Stock Master app.